Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Selective Hyper-responsiveness of the Interferon System in Major Depressive Disorders and Depression Induced by Interferon Therapy

  • Joerg F. Schlaak ,

    Contributed equally to this work with: Joerg F. Schlaak, Martin Trippler

    Affiliation Department of Gastroenterology and Hepatology, University Hospital of Essen, Essen, Germany

  • Martin Trippler ,

    Contributed equally to this work with: Joerg F. Schlaak, Martin Trippler

    Affiliation Department of Gastroenterology and Hepatology, University Hospital of Essen, Essen, Germany

  • Carolina Hoyo-Becerra,

    Affiliation Department of Gastroenterology and Hepatology, University Hospital of Essen, Essen, Germany

  • Yesim Erim,

    Affiliation Department of Psychosomatics, Rheinische Kliniken, Essen, Germany

  • Bernhard Kis,

    Affiliation Department of Psychiatry and Psychotherapy, LVR-Klinikum, Essen, Germany

  • Bo Wang,

    Affiliation Department of Gastroenterology and Hepatology, University Hospital of Essen, Essen, Germany

  • Norbert Scherbaum,

    Affiliation Addiction Research Group at the Department of Psychiatry and Psychotherapy, LVR-Klinikum, Essen, Germany

  • Guido Gerken

    Affiliation Department of Gastroenterology and Hepatology, University Hospital of Essen, Essen, Germany

Selective Hyper-responsiveness of the Interferon System in Major Depressive Disorders and Depression Induced by Interferon Therapy

  • Joerg F. Schlaak, 
  • Martin Trippler, 
  • Carolina Hoyo-Becerra, 
  • Yesim Erim, 
  • Bernhard Kis, 
  • Bo Wang, 
  • Norbert Scherbaum, 
  • Guido Gerken



Though an important percentage of patients with chronic hepatitis C virus (HCV) undergoing interferon (IFN) therapy develop depressive symptoms, the role of the IFN system in the pathogenesis of depressive disorders is not well understood.


50 patients with HCV infection were treated with standard combination therapy (pegylated IFN-α2a/ribavirin). IFN-induced gene expression was analyzed to identify genes which are differentially regulated in patients with or without IFN-induced depression. For validation, PBMC from 22 psychiatric patients with a severe depressive episode (SDE) and 11 controls were cultivated in vitro with pegylated IFN-α2a and gene expression was analyzed.


IFN-induced depression in HCV patients was associated with selective upregulation of 15 genes, including 6 genes that were previously described to be relevant for major depressive disorders or neuronal development. In addition, increased endogenous IFN-production and selective hyper-responsiveness of these genes to IFN stimulation were observed in SDE patients.


Our data suggest that selective hyper-responsiveness to exogenous (IFN therapy) or endogenous (depressive disorders) type I IFNs may lead to the development of depressive symptoms. These data could lead to the discovery of novel therapeutic approaches to treat IFN-induced and major depressive disorders.


Chronic hepatitis C virus (HCV) infection is a major cause for liver-related morbidity and mortality affecting approximately 170 million individuals worldwide. Around 70% of patients develop histological evidence of chronic liver disease, which may ultimately lead to liver cirrhosis and hepatocellular carcinoma [1]. In recent studies using pegylated interferon (IFN)-α2 in combination with ribavirin response rates for genotype 1 patients were approximately 40–50% while patients with genotype 2 or 3 respond in about 80–90% [2][4]. A major obstacle for this combination therapy, however, is the development of depressive side effects that is observed in 22–31% of patients [2][4].

There is an increasing body of evidence that point at depression as an inflammatory disorder prompted by deregulated levels of pro-inflammatory cytokines, such interleukin-1β, IL-6, tumor necrosis factor-α, IFN-γ and IFN-γ-induced protein 10 (IP-10) [5][9]. It is known that IFN-α is a pro-inflammatory innate immune cytokine that causes high rates of depression in humans. The IFN-α mediated depression has been widely reported in patients treated for hepatitis B, hepatitis C and malignant melanoma and can induce to suicidal behavior [7], [8], [10], [11]. Despite the increasing significance of this phenomenon, the molecular interactions underlying this outcome are poorly understood. Multiple mechanisms including immune, neurotransmitter and neuroendocrine pathways have been associated with IFN-α mediated depression, and a wide range of putative risk factors are being proposed and studied at genetic, molecular and behavioral levels. As cytokines affect the synthesis, release and cellular reuptake of monoamines and their dysregulation affects several central nervous system functions, it has been postulated that some neurophysiologic changes that affect activity of the noradrenergic and/or the serotonergic neuron system may occur during IFN therapy [12][14]. It has been shown that IFN-α can promote the depletion of serotonin by inducing the activation of indolamine 2,3 dioxygenase (IDO1), responsible of the conversion of tryptophan to kynurenine (12, 14, 15), and plays a crucial role as molecular mediator of inflammation-induced depressive-like behavior in mice [15][17]. Concomitantly, IFN-α may alter dopamine metabolism by changes in kynurenic acid, a tryptophan metabolite that can affect dopamine release, and decreased concentrations of tetrahydrobiopterin (BH4) as an enzyme cofactor for tyrosine hydroxylase, which is the rate limiting enzyme in the synthesis of dopamine (13, 15). Moreover, it has been shown that IFN-α is a potent inducer of mitogen activated protein kinase (MAPK) signaling pathways [18], that have been reported to activate monoamine transporters and thereby deplete their synaptic concentrations [13], [19]. Studies in experimental animals have revealed that IFN-α, when injected into the ventricular system, can suppress serotonin (5-HT) and dopamine levels in the striatum, frontal cortex and midbrain [12], [14]. IFN-α may also indirectly stimulate the hypothalamic-pituitary-adrenal axis, which is known to be overactive in depression, by inducing cytokines (e.g. IL-6), that activate this system [20][22]. Interestingly, administration of IFN-α to non-human primates has been associated with immune, neuroendocrine and behavioral responses similar to that observed in humans. Thus, it has been found to increase plasma adrenocorticotrophic hormone, cortisol and IL-6, to decrease corticotrophin-releasing factor and to promote a depressive-like, huddling behavior [23]. Concomitantly, most of these molecular alterations are represented by genetic signatures, which have been reported in a variety of studies relating the prevalence of genetic polymorphisms on monoamine- and interleukin- related pathways with the development of IFN-induced depression (i.e., IDO1, serotonin receptor and transporter polymorphisms [24][27], and IL-6 polymorphisms [24], reviewed in [28]). Some of them are widely studied in case of idiopathic depression as well (reviewed in [29]). The growing evidences about the role of exogenous IFN on depression have promoted that genetic surveys extend towards the study of the IFN-related pathways. Thus, polymorphisms in IFN receptor alpha 1 have been proposed as a risk factor for the development of depressive symptoms during IFN-α therapy [30]. Further studies in mice have suggested that systemic IFN-α treatment may also have a direct effect by upregulating IFN-stimulated genes (ISGs) in the brain with a profile very similar to peripheral organs [31]. Until this point it was not clear, however, which ISGs are directly or indirectly involved in the induction of depression.

Therefore, we have studied in vivo the primary transcriptional response to IFN-α in patients treated for chronic hepatitis C to identify target genes that mediate the depressive side effects of IFN-α. With the aim to conjugate both, idiopathic- and IFN-derived-depression genetic background, the results were further validated in vitro in psychiatric patients with a severe depressive episode.

Materials and Methods


A total of 50 treatment naïve patients with chronic hepatitis C that fulfilled standard inclusion criteria as described previously [3] were included into this single-site prospective study (Table 1). They were treated with pegylated IFN-α2a (Pegasys, Roche; 180 µg s.c. once weekly) in combination with oral ribavirin (body weight < 75 kg: 1000 mg/d; body weight > 75 kg: 1200 mg/d) for 12 months (HCV genotype 1/4, n = 41/1) or 6 months (HCV genotype 2/3, n = 1/7), respectively.

22 psychiatric patients hospitalized for a severe depressive episode (SDE) were prospectively analyzed to validate the target genes in an independent cohort. The diagnosis of a SDE was based on the psychiatric evaluation by a board-certified psychiatrist. The severity of depression was assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17) that is a common tool in clinical trials [32]. A recurrent depressive disorder was diagnosed in 17 patients (ICD-10: F33.2), one of them with psychotic symptoms (ICD-10: F33.3), 3 patients had a bipolar affective disorder with a severe depressive episode (ICD-10: F31.4), and two patients a severe depressive episode (ICD-10: F32.2).

All parts of study were approved by the local ethical committee at the University Hospital of Essen. Patients from both patient cohorts and relatives of the deceased gave their written informed consent.

Diagnosis of Depression During IFN Therapy

Before IFN therapy all HCV patients filled out questionnaires (Hospital Anxiety and Depression Scale (HADS) and Beck Depression Inventory (BDI)) to quantify possible preexisting depressive symptoms. Depression scores were measured three, six and twelve months after IFN therapy. The structured psychiatric interview Mini-DIPS was conducted in 47 patients with known or suspected pre-existing psychiatric disorders by a board-certified psychiatrist resulting in the diagnosis of previous intravenous heroin abuse (n = 8) and several psychiatric disorders (Table 1) in 15 of the patients. Patients with schizophrenia were treated with neuroleptic medication before and during IFN therapy. Three patients received antidepressive medication before initiation of therapy. Eleven patients developed moderate de novo depressive symptoms and were treated with antidepressive medication of citalopram 20 mg per day. Symptoms of depression improved under this therapy and no patient discontinued IFN therapy prematurely.

Isolation and in vitro Stimulation of PBMC

Blood samples were taken from healthy controls (n = 11) or patients hospitalized for a severe depressive episode (n = 22). Then, PBMC were isolated as previously described [33] and cultured for 16 h in the absence or presence of 100 U/mL pegylated IFN-α2a followed by isolation of total RNA as described later. All experiments were performed in triplicate under stringent endotoxin-free conditions.

Isolation of Total RNA from Peripheral Blood, Cultivated PBMC

For in vivo gene expression analysis, peripheral blood was collected directly into PAXgene Blood RNA Tubes (Becton Dickinson, Heidelberg, Germany) and RNA was isolated using the PAXgene Blood RNA Kit (Qiagen, Hilden, Germany) according to the instructions of the manufacturer.

For in vitro gene expression analysis, total RNA was isolated from cultivated PBMC using Trizol (Invitrogen, Karlsruhe, Germany) followed by a cleanup procedure using the RNeasy Mini Kit and the RNase-Free DNase Set (both from Qiagen) following the manufacturer’s protocol.

DNA Microarray Analysis

Double-stranded cDNA was synthesized from 20 µg of total RNA using Superscript II (Gibco, Gaithersburg, MD) and an oligo T-7-(dT)24 primer. cRNA was synthesized using a primer that contained a T-7 RNA polymerase site that is labeled with biotin-11-CTP and biotin-16-UTP using a BioArray T-7 polymerase labeling kit (Enzo, Farmingdale, NY) following the manufacturer’s protocol. Hybridizing, washing, antibody amplification, and staining of probe arrays are performed according to the instructions of the manufacturer. Experiments were performed using human genomic microarrays (HG-U133A 2.0, Affymetrix, Santa Clara, CA). GeneChip Operating Software (GCOS v1.2.0.037, Affymetrix) was used to perform absolute analyses of individual microarrays followed by comparison analyses between individual off- an on-treatment samples. Data filtering was performed using the Data Mining Tool software (DMT v3.1, Affymetrix).

Real-time Detection Gene Expression with One-step RT-PCR

In order to determine the gene expression levels of the candidate ISGs, endogenous IFNs and TLRs one-step RT-PCR with real-time detection was performed on the Rotor-Gene 2000 real-time amplification system (Corbett Research, Mortlake, Australia). One-step RT-PCR was carried out with the QuantiTect SYBR Green RT-PCR Kit (Qiagen) according to the manufacturer’s instructions as described before [34]. Three house-keeping genes β-actin (ACTB), tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein (YWHAZ), and β2-microglobulin (B2M) were quantified for normalization of gene copy numbers to the variable RNA amounts within the different samples. For each gene data are shown as copy numbers normalized to the number of ACTB transcripts in the sample.

Self-designed primers were used for ACTB, B2M, GBP1, IFIT1, ISG15, MX1, STAT1, and YWHAZ (Table 2). For all other genes commercial primers were used (QuantiTect Primer Assay, Qiagen).

Statistical Methods

Prior to significance and prediction analyses the different chip raw data were normalized by means of background adjustment and quantile normalization using the RMAExpress v0.4.1 software [35]. To identify genes which are differentially expressed in HCV patients with or without IFN induced depression the Significance Analysis of Microarrays (SAM v3.0) Excel add-in was used [36]. SAM computes repeated permutations of the data to determine if the expression of any genes are significantly related to a given response variable (i.e. before or after IFN treatment). The cut off for significance is determined by a tuning parameter delta, chosen to minimize the false positive rate.

Class prediction analysis was performed using the Prediction Analysis for Microarrays (PAM v2.1) Excel add-in to identify genes that best characterize each of two given classes (IFN induced depression or no depression) using the nearest shrunken centroid method [37].

Statistical analysis of the gene expression levels was performed using the T-Test or Mann-Whitney test as appropriate using the GraphPad Prism software (version 4.03). The null hypothesis was rejected at the p≤0.05 level.


As described previously, 22% (11/50) of the HCV patients treated with pegylated IFN-α2a and ribavirin developed depressive side effects during therapy [3]. Development of depressive side effects did not correlate with response to therapy, sex, age, ALT-levels, presence of cirrhosis, HCV genotype, viral load before therapy or response to therapy (data not shown).

To identify candidate genes which mediate the depressive side effects of IFN-α, microarray analysis of the primary transcriptional response to IFN-α was performed in those 11 patients that developed depression during therapy in comparison to 11 randomly chosen HCV patients that did not experience such side effects. Using significance and class prediction analysis, a total of 15 genes were identified that were selectively hyper-responsive to exogenous IFN-α in patients that developed depressive side effects (Table 3). In addition, considering the previous reported association with IFN-related depression [13], [18], [19], [38], the microarray results of IP-10 and IDO1 underwent statistical analysis. Although a trend towards an increased expression was observed, changes were not statistically significant which may be due to the small sample population and the very early time point (12h) studied after IFN injection (data not shown).

To validate these candidate genes in different patient populations under different experimental conditions, the in vitro response to pegylated IFN-α2a was studied in a cohort of 22 psychiatric patients that were hospitalized for a SDE. Compared to healthy controls, pegylated IFN-α2a led to a significantly higher induction of GCH1, TOR1B (Figure 1A), DYNLT1 and DISC1 (Figure 1B) while there was a trend towards higher induction for MEF2A and ST3GAL5 (data not shown). No difference was observed for classical ISGs like MX1 or ISG15 (Figure 1C) as well as IFIT1 and IFI16 (data not shown) suggesting that there is a selective rather than a general hyper-responsiveness to type I IFNs in these patients.

Figure 1. Enhanced IFN-mediated induction of selective ISGs in HCV patients with IFN-induced depression (in vivo) and psychiatric patients with a severe depressive episode (SDE, in vitro).

Total RNA was isolated from peripheral blood of hepatitis C virus (HCV) infected patients with (n = 11, “HCV-D”) or without (n = 11, “HCV-N”) IFN-induced depression 12 hours before and 12 hours after the first injection of pegylated IFN-α2a. Expression of IFN stimulated genes (ISGs) was analyzed by quantitative RT-PCR (panel A: GCH1, TOR1B; panel B: DYNLT1, DISC1; panel C: MX1, ISG15). To validate the data in an independent cohort, PBMC were isolated from 11 healthy controls (“co-N”) and 22 patients hospitalized for a SDE (“co-D”) and stimulated with 100 U/mL pegylated IFN-α2a in vitro for 16 h followed by isolation of total RNA. Data are shown as box plots (range, 25% and 75% percentile, mean).

When baseline levels of ISGs were studied in patients with SDE after 24h without additional stimulation, a significant upregulation of classical ISGs (i.e. STAT1, IFIT1) compared to healthy controls was observed (Figure 2A) suggesting that there is an increased production of endogenous IFNs in these patients. To test this hypothesis, we assessed the in vivo baseline levels of the most abundant IFN-α subtypes (IFN-α1 and -α2), IFN-β and IFN-γ by quantitative RT-PCR (Table 4, Figure 2B). The most striking finding was a significant upregulation of IFN-β production in patients with SDE compared to controls. Also, there were increased mRNA levels of IFN-α1 and IFN-α2 and a trend towards higher levels of IFN-γ suggesting a broad activation of type I and II IFN production in SDE patients. Interestingly, IFN-β expression was profoundly enhanced in HCV patients before therapy consistent with a direct stimulation by HCV through the Toll-like receptor (TLR) system (Table 4). IFN-γ mRNA levels were elevated in HCV patients that could be explained by activation of the PBMC-derived immunity while no significant changes in IFN-α mRNA levels were observed.

Figure 2. Enhanced ISG expression and IFN-production in psychiatric patients with a severe depressive episode (SDE).

Panel A. After 24 h of in vitro incubation without any further stimuli, total RNA was isolated from peripheral blood mononuclear cells of 11 healthy controls (“co-N”) and 22 patients hospitalized for a SDE (“co-D”). Panel B. Total RNA was isolated directly from unseparated peripheral blood of healthy controls (“co-N”, n = 11), SDE patients (“co-D, n = 22”) and HCV patients without (“HCV-N”, n = 11) or with (“HCV-D”, n = 11) IFN-induced depression. Expression of IFN stimulated genes (ISGs) and IFN-β was analyzed by quantitative RT-PCR. Data (copies per 100,000 copies of ACTB) are shown as box plots (range, 25% and 75% percentile, mean).

Table 4. Basal expression of interferons and toll-like receptor genes in individuals with or without depressive disorders.

Type I and II IFNs were significantly upregulated in depressive individuals confirming the results from the peripheral blood of SDE patients (Table 4). Interestingly, we also found an upregulation of TLR3 and TLR7 that function as sensors of the innate immune system for viral structures in particular, reviewed in [39]. In HCV-positive individuals a significant upregulation of IFN-β was observed (p<0.005) compared to HCV-negative individuals.


Determining the role of genetic vulnerability to harmful side effects is becoming a crucial issue in order to progress toward individualized drug therapy with successful outcome. A major obstacle of IFN therapy for chronic hepatitis C is that about a quarter of these patients will develop depressive side effects that can even lead to suicide in some cases [2], [3]. The pathophysiology of IFN-induced depression, however, is not well understood. Most of the molecular dysregulations observed in IFN-related depression are similar to those described for idiopathic depression, suggesting the existence of common pathways to both disorders. In fact, the monocyte-T-lymphocyte hypothesis of mayor depression predicts an immune system activation subjacent to the pathophysiology of major depressive disorder [40], and the association of the depressive symptoms with an increased production of pro-inflammatory cytokines [5][8] may indicate that they are the result of a maladaptive response to immune activation. Pegylated IFN-α and ribavirin therapy, as source of an artificial pro-inflammatory cytokine, has been related to the risk of develop depressive behavior by affecting the monoamine and cytokine balance, but a common genetic background with idiopathic depression is not yet elucidated. Our data suggest that the development of depressive side effects during therapy with pegylated IFN-α and ribavirin for chronic hepatitis C is associated with a selective hyper-responsiveness of the IFN system. This leads to the disproportional upregulation of 15 genes including 6 genes that were previously reported to be relevant for recurrent major depression or neuronal development in the brain. The relevance of these genes was validated in a separate cohort of psychiatric patients hospitalized for a severe depressive episode by analyzing the in vitro induction of these ISGs by pegylated IFN-α. In these cohorts, we were also able to demonstrate enhanced basal production of endogenous IFNs, which may contribute to the cytokine levels dysregulation. The 15 target genes include DYNLT1, GCH1, TOR1B, DISC1, MEF2A and ST3GAL5 that to date were never related to an IFN-α regulation while all of them have been described in association with brain development or depression. TOR1B, which shows immunoreactivity in all subfields of the hippocampus [41], is homologue to TOR1A (alternative name: DYT1), is associated with early-onset recurrent major depression and is involved in the regulation of dopamine release [42]. DYNLT1 (alternative name: TCTEL1) plays a key role in multiple steps of hippocampal neuron development such as neurite sprouting, axon specification and dendritic elaboration [43]. MEF2A is also involved in neuronal differentiation and postsynaptic differentiation [44][46]. DISC1 plays a role in neurite outgrowth and cortical development and contributes to alterations of hippocampal structure and function [47], [48]. Furthermore, genetic analyses revealed an association with schizophrenia and major depression [49][52]. ST3GAL5 is involved in neuronal apoptotic cell death in mouse hippocampal cell lines [53]. Finally, GCH1 is the rate-limiting enzyme in BH4 biosynthesis, an essential cofactor required by the aromatic amino acid hydroxylase and nitric oxide synthase which are in turn the rate-limiting enzymes in dopamine and serotonin biosynthesis. Interestingly, it has already been shown that different IFN types, including pegylated-IFN forms, are able to induce GCH1 activation with the subsequent increase of BH4 and its precursor neopterin, released from monocytes and macrophages [54], [55], which has been widely used as a pharmacodynamic marker in the evaluation and optimization of IFN therapy [56], [57]. Even more, several authors have lately reported that IFN-α therapy impairs phenylalanine metabolism in HCV infected individuals [58], [59], suggesting that behavioural side effects may be associated with the modulation of BH4 levels, thus affecting dopamine, serotonin and noradrenaline biochemistry. Clinically, alterations of GCH1 activity has been associated with bipolar disorders, depression, anxiety, dystonia and deafness [60], [61]. The hippocampus is one of several limbic brain structures implicated in the pathophysiology and treatment of mood disorders. Recently, it has been suggested that depression may have a neurogenic origin as loss of neurons in the adult hippocampus is observed and neurogenesis is required for the actions of antidepressants [62], [63]. Furthermore, it has been demonstrated that exogenous administration of IFN-α suppressed neuronal proliferation via proinflammatory cytokines IL-1β and TNF-α in the hippocampus of adult rats [64]. Previous studies revealed that the exposition to these cytokines induce depressive symptoms in humans and depression-like behavior in animals. Latter findings even related specifically increased plasma levels of the mentioned cytokines to the cause of severe depressive symptoms in HCV patients [65]. Our data suggest that IFN-α may interfere with these processes through modulation of the target genes identified in this study.

Patients with chronic HCV infection often report fatigue, depressive mood, impaired cognitive functions, and reduced quality of life [66][68]. As these symptoms do not correlate with severity of liver disease, hepatic encephalopathy, or history of intravenous drug use [66], it has been speculated that HCV itself may cause these alterations. This is supported by the fact that HCV RNA is detectable in the brain [69] or in cerebrospinal fluid leading to the hypothesis that HCV may cross the blood brain barrier by infected monocytes which could result in secondary infection of microglial cells [70]. It is well known that HCV can activate the production of IFN-β through activation of the Toll-like receptor system [71], [72], which explains the strong upregulation of IFN-β in the peripheral blood of HCV patients in our study. Microarray studies have indicated that increased type I IFN production occurs also in the livers of HCV-infected chimpanzees and humans [73], [74]. Therefore, we hypothesize that this endogenous IFN production may, at least in part, explain the depressive and cognitive disorders that are frequently seen in these patients.

Only little is known about the relevance of the IFN system for depressive episodes in the course of affective disorders. In accordance with our mRNA data, it has been shown that plasma levels of IFN-γ are higher in patients with depression [75]. Though the role of type I IFNs is still not well understood, it has been reported that they may help sustain the chronic inflammatory response promoting the recruitment of inflammatory monocytes [76] which may be involved in the pathophysiology of the depressive symptoms. In this context, our findings may point to a direct implication of monocyte/macrophage activation by IFN-α with an alteration of the tryptophan metabolism and the subsequent neurotransmitter dysregulation through GCH1 modulation.

According to our results, this study may have major implications regarding a) the pathophysiology of IFN-induced depression, b) the pathophysiology of depressive disorders and cognitive dysfunctions in HCV patients and c) the relevance of the IFN system for severe depressive episodes in psychiatric diseases. Still, possible limitations regarding the relative small sample size, the different medical treatment taken by some HCV and psychiatric patients or comparison of related but not identical psychiatric disorders must be considered. Our study design does not allow to clearly differentiate the alterations solely related to interferon therapy from another medication, drug or altered physiological condition. This would be possible to resolve by studying only patients without any previous psychiatric history and treatment, but such a group would be too difficult to obtain due to the demographic characteristics of HCV and psychiatric patients. Thus, the conclusions presented here need to be confirmed in independent larger cohorts. Nevertheless, this work provides valuable information about the possible mechanisms underlying depression and other cognitive dysfunctions affecting HCV patients treated with the current standard therapy and, as a last resort, giving the likelihood to try to prevent, mitigate or avoid such side effects. Collectively, our results extend across two completely different clinical scenarios to generate convergent data that bridge the phenomenon of IFN-induced depression and major depression and thereby provide a pathophysiologic mechanism of depressive disorders focused on the role of inflammatory cytokines.

In conclusion, these data suggest that selective hyper-responsiveness to exogenous or endogenous type I IFNs may lead to the development of depressive symptoms. This sheds new light on the pathogenesis of IFN-induced and depressive episodes and could ultimately lead to the discovery of novel therapeutic approaches to treat these conditions.

Author Contributions

Conceived and designed the experiments: JS. Performed the experiments: MT YE BK BW NS. Analyzed the data: JS MT CH. Contributed reagents/materials/analysis tools: MT YE BK. Wrote the paper: JS MT YE CH GG.


  1. 1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH (2000) Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132: 296–305.
  2. 2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965.
  3. 3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982.
  4. 4. Asnis GM, De La Garza R (2006) Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 40: 322–335.
  5. 5. Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71: 171–186.
  6. 6. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, et al. (2009) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24: 27–53.
  7. 7. Pasquali S, Mocellin S (2010) The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma. Curr Med Chem 17: 3327–3336.
  8. 8. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, et al. (2005) Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 66: 41–48.
  9. 9. Wong ML, Dong C, Maestre-Mesa J, Licinio J (2008) Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 13: 800–812.
  10. 10. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, et al. (2005) Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 19: 23–27.
  11. 11. Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27: 24–31.
  12. 12. Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T (2000) Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 10: 129–132.
  13. 13. Morikawa O, Sakai N, Obara H, Saito N (1998) Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349: 317–324.
  14. 14. Kitagami T, Yamada K, Miura H, Hashimoto R, Nabeshima T, et al. (2003) Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res 978: 104–114.
  15. 15. O'Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, et al. (2009) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14: 511–522.
  16. 16. O'Connor JC, Lawson MA, Andre C, Briley EM, Szegedi SS, et al. (2009) Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 182: 3202–3212.
  17. 17. O'Connor JC, Andre C, Wang Y, Lawson MA, Szegedi SS, et al. (2009) Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 29: 4200–4209.
  18. 18. Zhao LJ, Hua X, He SF, Ren H, Qi ZT (2011) Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells. Virol J. 8.
  19. 19. Miller AH (2009) Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun 23: 149–158.
  20. 20. Shimizu H, Ohtani K, Sato N, Nagamine T, Mori M (1995) Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration. Endocr J 42: 551–556.
  21. 21. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, et al. (2003) Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 160: 1342–1345.
  22. 22. Wichers MC, Kenis G, Koek GH, Robaeys G, Nicolson NA, et al. (2007) Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res 62: 207–214.
  23. 23. Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, et al. (2007) Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry 62: 1324–1333.
  24. 24. Bull SJ, Huezo-Diaz P, Binder EB, Cubells JF, Ranjith G, et al. (2009) Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 14: 1095–1104.
  25. 25. Kraus MR, Al-Taie O, Schafer A, Pfersdorff M, Lesch KP, et al. (2007) Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 132: 1279–1286.
  26. 26. Smith AK, Simon JS, Gustafson EL, Noviello S, Cubells JF, et al. (2011) Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-alpha-induced depression in patients with chronic hepatitis C. Mol Psychiatry [Epub ahead of print].
  27. 27. Zhang P, Papenfuss TJ, Wake MH, Qu L, Wake DB (2008) Phylogeny and biogeography of the family Salamandridae (Amphibia: Caudata) inferred from complete mitochondrial genomes. Mol Phylogenet Evol 49: 586–597.
  28. 28. Smith KJ, Norris S, O'Farrelly C, O'Mara SM (2011) Risk factors for the development of depression in patients with hepatitis C taking interferon-alpha. Neuropsychiatr Dis Treat 7: 275–292.
  29. 29. Uher R (2011) Genes, environment, and individual differences in responding to treatment for depression. Harv Rev Psychiatry 19: 109–124.
  30. 30. Yoshida K, Alagbe O, Wang X, Woolwine B, Thornbury M, et al. (2005) Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology 52: 55–61.
  31. 31. Wang J, Campbell IL, Zhang H (2007) Systemic interferon-alpha regulates interferon-stimulated genes in the central nervous system. Mol Psychiatry 13: 293–301.
  32. 32. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62.
  33. 33. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, et al. (1994) T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 102: 145–149.
  34. 34. Broering R, Wu J, Meng Z, Hilgard P, Lu M, et al. (2008) Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 48: 914–922.
  35. 35. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185–193.
  36. 36. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116–5121.
  37. 37. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567–6572.
  38. 38. Wong ML, Dong C, Maestre-Mesa J, Licinio J (2008) Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 13: 800–812.
  39. 39. Broering R, Lu M, Schlaak JF (2011) Role of Toll-like receptors in liver health and disease. Clin Sci (Lond) 121: 415–426.
  40. 40. Elomaa AP, Niskanen L, Herzig KH, Viinamaki H, Hintikka J, et al. (2012) Elevated levels of serum IL-5 are associated with an increased likelihood of major depressive disorder. BMC Psychiatry. 12.
  41. 41. Konakova M, Huynh DP, Yong W, Pulst SM (2001) Cellular distribution of torsin A and torsin B in normal human brain. Arch Neurol 58: 921–927.
  42. 42. Heiman GA, Ottman R, Saunders-Pullman RJ, Ozelius LJ, Risch NJ, et al. (2004) Increased risk for recurrent major depression in DYT1 dystonia mutation carriers. Neurology 63: 631–637.
  43. 43. Chuang JZ, Yeh TY, Bollati F, Conde C, Canavosio F, et al. (2005) The dynein light chain Tctex-1 has a dynein-independent role in actin remodeling during neurite outgrowth. Dev Cell 9: 75–86.
  44. 44. Mao Z, Bonni A, Xia F, Nadal-Vicens M, Greenberg ME (1999) Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286: 785–790.
  45. 45. Flavell SW, Cowan CW, Kim TK, Greer PL, Lin Y, et al. (2006) Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number. Science 311: 1008–1012.
  46. 46. Shalizi A, Gaudilliere B, Yuan Z, Stegmuller J, Shirogane T, et al. (2006) A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 311: 1012–1017.
  47. 47. Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, et al. (2005) Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci U S A 102: 8627–8632.
  48. 48. Kamiya A, Kubo K, Tomoda T, Takaki M, Youn R, et al. (2005) A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol 7: 1167–1178.
  49. 49. Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, et al. (2001) Schizophrenia and affective disorders–cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 69: 428–433.
  50. 50. Hennah W, Varilo T, Kestila M, Paunio T, Arajarvi R, et al. (2003) Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects. Hum Mol Genet 12: 3151–3159.
  51. 51. Sawamura N, Sawamura-Yamamoto T, Ozeki Y, Ross CA, Sawa A (2005) A form of DISC1 enriched in nucleus: altered subcellular distribution in orbitofrontal cortex in psychosis and substance/alcohol abuse. Proc Natl Acad Sci U S A 102: 1187–1192.
  52. 52. Kato T (2001) Molecular genetics of bipolar disorder. Neurosci Res 40: 105–113.
  53. 53. Sohn H, Kim YS, Kim HT, Kim CH, Cho EW, et al. (2006) Ganglioside GM3 is involved in neuronal cell death. FASEB J 20: 1248–1250.
  54. 54. Huber C, Fuchs D, Hausen A, Margreiter R, Reibnegger G, et al. (1983) Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol 130: 1047–1050.
  55. 55. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, et al. (1984) Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 160: 310–316.
  56. 56. Gastl G, Aulitzky W, Tilg H, Nachbaur K, Troppmair J, et al. (1986) A biological approach to optimize interferon treatment in hairy cell leukemia. Immunobiology 172: 262–268.
  57. 57. Hu X, Miller L, Richman S, Hitchman S, Glick G, et al. (2011) A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology. J Clin Pharmacol [Epub ahead of print].
  58. 58. Bezemer G, Van Gool AR, Fekkes D, Vrolijk JM, Hansen BE, et al. (2012) Psychiatric Side Effects and Fluctuations in Serotonergic Parameters in the Treatment of Chronic Hepatitis C Infection. Neuropsychobiology 65: 126–132.
  59. 59. Zoller H, Schloegl A, Schroecksnadel S, Vogel W, Fuchs D (2011) Interferon-Alpha Therapy in Patients with Hepatitis C Virus Infection Increases Plasma Phenylalanine and the Phenylalanine to Tyrosine Ratio. J Interferon Cytokine Res [Epub ahead of print].
  60. 60. Hahn H, Trant MR, Brownstein MJ, Harper RA, Milstien S, et al. (2001) Neurologic and psychiatric manifestations in a family with a mutation in exon 2 of the guanosine triphosphate-cyclohydrolase gene. Arch Neurol 58: 749–755.
  61. 61. Kealey C, Roche S, Claffey E, McKeon P (2005) Linkage and candidate gene analysis of 14q22–24 in bipolar disorder: support for GCHI as a novel susceptibility gene. Am J Med Genet B Neuropsychiatr Genet 136: 75–80.
  62. 62. Li Y, Luikart BW, Birnbaum S, Chen J, Kwon CH, et al. (2008) TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 59: 399–412.
  63. 63. Perera TD, Dwork AJ, Keegan KA, Thirumangalakudi L, Lipira CM, et al. (2011) Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates. PLoS One. 6.
  64. 64. Kaneko N, Kudo K, Mabuchi T, Takemoto K, Fujimaki K, et al. (2006) Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 31: 2619–2626.
  65. 65. Loftis JM, Huckans M, Ruimy S, Hinrichs DJ, Hauser P (2008) Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci Lett 430: 264–268.
  66. 66. Foster GR, Goldin RD, Thomas HC (1998) Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 27: 209–212.
  67. 67. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, et al. (2001) Evidence for a cerebral effect of the hepatitis C virus. Lancet 358: 38–39.
  68. 68. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, et al. (2002) Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 35: 433–439.
  69. 69. Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC (2004) Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 78: 5170–5183.
  70. 70. Laskus T, Radkowski M, Bednarska A, Wilkinson J, Adair D, et al. (2002) Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol 76: 10064–10068.
  71. 71. Kanda T, Steele R, Ray R, Ray RB (2007) Hepatitis C virus infection induces the beta interferon signaling pathway in immortalized human hepatocytes. J Virol 81: 12375–12381.
  72. 72. Wu J, Lu M, Meng Z, Trippler M, Broering R, et al. (2007) Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 46: 1769–1778.
  73. 73. Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, et al. (2004) Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 78: 13779–13792.
  74. 74. Chen L, Borozan I, Feld J, Sun J, Tannis LL, et al. (2005) Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128: 1437–1444.
  75. 75. Myint AM, Leonard BE, Steinbusch HW, Kim YK (2005) Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 88: 167–173.
  76. 76. Lee PY, Li Y, Kumagai Y, Xu Y, Weinstein JS, et al. (2009) Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am J Pathol 175: 2023–2033.